

Contents

Volume 24, 1990

Volume 24, Number 1

1990

CONTENTS

Rx-to-OTC Switch

R. William Soller	1	Introduction
William E. Cooley	3	Overview by the Moderator
Robert G. Pinco	5	A Legal Perspective on Regulatory Approaches to Switch
Jerome A. Halperin	13	Strategic Issues in the Rx-to-OTC Switch
William E. Cooley	19	Discussion Panel
Paula Botstein	29	Criteria for Switching New Molecular Entities from Prescription to Over-the-Counter
William E. Gilbertson	33	Criteria For GRAS and GRAE Status for Switch Via the Monograph
Henry A. Palmer	41	OTC Information: Labeling Demands and Beyond
William E. Cooley	45	Question and Answer Session
Jonathan C. Peck	49	Future Health Care Trends Affecting Rx-to-OTC Switch
Stephen W. Schondelmeyer	57	Economic Aspects of Switch
William E. Cooley	67	Question and Answer Session
R. William Soller	73	Welcome and Introduction
Mark Novitch	75	Overview of the Health Professional Panel on Switch
Thomas Q. Garvey III	77	Switch Candidates from the GI Perspective
Leslie Hendeles	83	Switch Candidates from the Pulmonary Perspective

Howard I. Maibach	91	Switch Candidates from the Dermatological Perspective
Norman W. Lavy	95	Switch Candidates from the Internal Medicine Perspective
Mark Novitch	99	Health Professional Panel
Arthur Hull Hayes Jr	111	Overview of the Proceedings: The Future of Switch
Additional Articles		
A. C. Cartwright	115	Stereochemistry and Safety, Efficacy and Quality Issues: Genesis of New Regulations
Jeffrey R. Brown	117	Stereochemical Principles
Andrew K. Scott	121	Stereoisomers in Clinical Pharmacology
Charles S. Kumkumian	125	Regulatory Considerations Concerning Stereoisomers in Drug Products
Roger A. Sheldon	129	The Industrial Synthesis of Pure Enantiomers
Akira Kawahara	141	Regulatory Aspects of Biotechnology in Japan
Akira Kawahara	153	Present and Future Aspects of the Japanese Pharmaceutical Affairs Administration
R. Graham Hughes	169	The Management of Third-Party Trials in Europe
Theresa E. Stokes	177	Clinical Data Management — Technology Trends Survey
Vincente Anido Jr Ashok K. Gumbhir Suzan N. Kucukarslan	189	Comparison of Missouri and Kansas Community Pharmacists' Communication Performance
Georges Lagier René Jean Royer	203	Information to the Physician: Role of French Regional Pharmacovigilance Centres
Kenneth I. Kaitin	207	Impact of Policy Research on Drug Development Strategies
Ralph D. Harkins Renata Albrecht	213	Design and Analysis of Clinical Trials for Anti-Infective Drug Products
Thomas R. Beam Jr David N. Gilbert Calvin M. Kunin	225	Updated Guidelines for the Evaluation of New Anti-Infective Drug Products

- Louis Lasagna** 231 On Achieving Consensus Regarding Flexible Therapeutic End Points
- Robert P. Baker** 235 User Survey of an Industry-Based Drug Information Service
- Thomas H. Perez** 245 Adverse Reaction Reporting Requirements: An Update for Manufacturers
- Paul L. Gittelson** 251 A Quality Assurance Program for Sponsored Clinical Trials
- Karl E. Peace** 257 TMO: The Trial Management Organization—A New System for Reducing the Time for Clinical Trials
- I Software Survey Section:
*PC! info: Time-Oriented Data Management/
Analysis System*
Parnassa Regulatory Affairs Document Manager
-
-

Volume 24, Number 2

1990

CONTENTS

**Statistical Issues in Pharmaceutical Industry:
Experimental Design Considerations in Drug Development**

- John R. Schultz** 265 Introduction
- David Salsburg** 267 Mathematical Modeling and the Design of Studies in Drug Research
- Carl M. Metzler** 281 Medical and Statistical Design Issues in Clinical Pharmacology
James T. VanderLugt
- Lianng Yuh** 289 Latin Square Designs in a Comparative Bioavailability Study
Stephen J. Ruberg
- H. J. Rostami** 299 Experimental Design for Pharmacokinetics Modeling
- Donald J. Schuirmann** 315 Design of Bioavailability/Bioequivalence Studies
- Jonathan B. Skinner** 325 Early Exploration of Safety and Efficacy
- Nancy L. Geller** 341 Design of Phase I and II Trials in Cancer

- | | | |
|--|-----|--|
| Walter H. Carter, Jr
Bruce E. Dornseif | 351 | Maximizing Drug Benefit in Combination Therapy
(Dose-Response Estimation) |
| Mary F. Johnson | 361 | Issues in Planning Interim Analyses |
| H. M. James Hung
Tie-Hua Ng
George Y. H. Chi
Raymond J. Lipicky | 371 | Response Surface and Factorial Designs for
Combination Antihypertensive Drugs |
| Lilly P. Sanathanan | 379 | Introduction: Statistical Issues in Animal Safety
Studies |
| Daniel Krewski
Michael Goddard | 381 | Principles of Bioassay Design |
| Patrick J. Wier
John R. Ventre | 395 | Statistical Analyses of Reproductive and
Developmental Toxicology Studies |
| Gary G. Koch
Sandra Stinnett
William A. Sollecito | 407 | Summary and Discussion for Experimental Design
Considerations in Drug Development |

Additional Articles

- | | | |
|---|-----|--|
| Gerald A. Faich
Winifred Castle
Zbigniew Bankowski
The CIOMS ADR Working
Group | 419 | International Adverse Drug Reaction Reporting: The
CIOMS Project |
| Jan Rosier
Paul Demoen | 427 | Requirements for Chemical and Pharmaceutical
Data in Support of Clinical Trial Applications in the
United Kingdom, Canada, the USA, the Nordic
Countries, and Australia |
| | 449 | Letter to the Editor |
| | I | Software Survey Section |

CONTENTS

- | | | |
|---------------------------|-----|--|
| Michael R. Hamrell | 451 | FDA Perspective on Computer Assisted
Pharmacology/Toxicology Review |
|---------------------------|-----|--|

- Rodney Charles Hall** 457 Collaboration Between Australia and Sweden in
Drug Regulation
Paul Isaacson
Per Sjoberg
Ture Sjoblom
Kjell Strandberg
Olof Tyden
- Bette Lee Barton** 463 FDA's Inspections of US and Non-US Clinical
Studies
- Stephen G. Bryant** 469 Postmarketing Surveillance: Effects of
Compensation on Patient Self-Monitoring
Seymour Fisher
David B. Larson
Nancy J. Olins
- Brian L. Strom** 477 Medicaid Billing Data Used to Study the Effects of
Marketed Drugs
Jeffrey L. Carson
- Uli Hacksell** 485 Stereoselectivity of Drug Receptor Interactions
Lars-Erik Arvidsson
Anette M. Johansson
Anders Karlén
Kristina Luthman
Stephan Hjorth
- Robert E. Pearson** 497 Contribution of Computerized Content Analysis to
Visualization of *USP DI*
Bill G. Felkey
J. Tyrone Gibson
Kenneth N. Barker
- Raymond W. Falk** 507 Basic Guidelines for Inference From Clinical Trial
Data
- Charlotte A. Jankel** 513 The Effectiveness of Computerized Drug Interaction
Screening Programs in Hospitals
John A. McMillan
Stuart M. Speedie
- William E. Cwiklo** 531 Standards for CANDAs; Do CALS Standards Point
the Way?
B. Tommie Usdin
- Nancy E. Nazari** 537 ICI's Patient Assistance Program
Yvonne Graham
- Gregory G. Enas** 541 Baseline Comparability in Clinical Trials: Prevention
of "Poststudy Anxiety"
Nathan H. Enas
C. Thomas Spradlin
Michael G. Wilson
Curtis G. Wiltse
- L. S. Kaufman** 549 Clinical Study Authorizations: Development
Strategies
C. S. Snoddy, Jr

- | | | |
|--|-----|---|
| Phn Nelly Baudrihay | 561 | Events and Milestones on the Road to 1992 – The Needs of Industry in View of the Internal Market and Evolving Regulatory Procedures |
| Bjørn Jøldal | 569 | EFTA/EEC: A Review of Progress in the Harmonization of Regulatory Requirements; Collaboration and Interaction Between Authorities; the PIC and the PER Scheme |
| Martha M. Meinzinger
William S. Barry | 575 | Prospective Study of the Influence of the Media on Reporting Medical Events |
| Paul Mensinga
Danielle Gabarra | 579 | Clinical Quality Assurance: A Method for the Quantification of In-House Audits |
| Jan Rosier
Paul Demoen | 583 | Labeling of Clinical Trial Samples: An Overview of Some Regulatory Requirements |
| Robert H. Denlinger | 591 | Industry Perspective on Computer Assisted Toxicology/Pharmacology Review |
| J. Greg Perkins
Michael Dalton
George M. Lyon | 597 | Utility of Retrovir's® Phase IV Research From a Regulatory Perspective |
| Charles F. Curran
Osman Bawa | 605 | Implementation of a Worldwide Drug Safety Surveillance System |
| Peter P. Lamy | 615 | Patient Package Inserts: The Voluntary Approach |
| Harry Irving Katz
Sheila L. Katz
Lionel D. Edwards
John J. Mooney | 621 | Survey Results of Remote Data Entry Use by Clinical Investigator Sites |
| Lionel D. Edwards | 629 | Multinational Experience Using Remote Data Entry in Clinical Studies |
| S. Mela | 635 | European Communities: Outstanding White Paper Proposals for the Completion of Internal Market in the Pharmaceutical Sector |
| Louis A. Morris
David B. Banks | 639 | New Issues in Drug Advertising and Labeling: The Five Advertising End-Runs |
| | I | Software Survey Section:
<i>Scratchcard Analysis</i>
<i>BioGraf</i>
<i>IRB info: Institutional Review Board Data Management System</i>
<i>Entrypoint 90</i> |

CONTENTS

Preclinical Computer and Statistical Applications

- | | | |
|--|-----|---|
| Karl E. Peace | 647 | Introduction |
| Seth Michelson
Mark Bradshaw
Chuck Villarrubia
Bruce Ingraham | 649 | PEAS—A Parameter Estimation Analysis System:
An In-Laboratory Analysis Tool |
| Eric M. Chi | 659 | Analysis of Longitudinal Data by Models with
Random Effects and AR(1) Errors |
| C. Thomas Lin | 671 | Applications of Partial Least Squares to Spectral
Data for Quantitative Determinations of Chemicals
in a Mixture |
| Peter C. Jurs
Richard G. Lawson | 691 | Clustering Tendency Applied to Chemical Feature
Selection |
| James W. McFarland
Daniel J. Gans | 705 | Cluster Significance Analysis: A New QSAR Tool for
Asymmetric Data Sets |
| Jia-Lin Syi
Rick Gussio
Jih-Hsiang Chen | 713 | Investigation of the Dissociation Process of the
Inhibitor Methotrexate from the
Methotrexate-Lactobacillus Casei Dihydrofolate
Reductase Complex by Using Molecular Dynamics
and Semiempirical Molecular Orbital Methods |
| Mirza W. Ali | 727 | Exact Versus Asymptotic Tests of Trend of Tumor
Prevalence in Tumorigenicity Experiments: A
Comparison of <i>P</i> -Values for Small Frequency of
Tumors |
| Kem F. Phillips | 739 | The Statistical Analysis of Data from Bioequivalence
Studies Using Stable Isotopes |
| Lianng Yuh | 747 | Robust Procedures in Comparative Bioavailability
Studies |
| Shein-Chung Chow | 753 | Alternative Approaches for Assessing Bioequivalence
Regarding Normality Assumptions |
| Additional Articles | | |
| Rona S. Wasserman | 763 | Use of an Electronic Publishing System for
Production of Pharmaceutical Product Literature |

- | | | |
|----------------------------|------------|---|
| Terry L. Gillum | 769 | Dictionary Design for Clinical Data Management |
| Elisabetta Ortelli | 775 | Present and Future of a Private Biomedical Database |
| Aldo Ferrario | | |
| Alan Gelberg | 785 | A Study of the Utilization of the FDA's Adverse Drug Reaction Database |
| George D. Armstrong | | |
| Frances O. Kelsey | 795 | FDA Perspective on IRBs and Overview of FDA Inspection of IRBs |
| | | |
| | I | Software Survey Section: |
| | | <i>HASL v. 3.17</i> |
| | | |
| | V | Volume 24 Contents and Author Index |

